Document is current

Article History

Received: 29 July 2024

Accepted: 31 October 2024

First Online: 5 December 2024

Declarations

:

: Hillary Norton has received grants and/or research support from AbbVie, Eli Lilly, Horizon, Novartis, and Scipher; has been an advisor for AbbVie, Amgen, AstraZeneca, Eli Lilly, Horizon, Janssen, Novartis, Pfizer Inc., Scipher, and UCB; and has been a member of the speakers’ bureau for AbbVie, Amgen, Eli Lilly, Janssen, Horizon, Novartis, Sanofi-Aventis, and UCB. Paula Sliwinska-Stanczyk and Tomas Hala have no disclosures. Bassel El-Zorkany has received grants and/or research support from Pfizer Inc. and Roche and has acted as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Eva, Hekma, Inspire, Janssen, MSD, New Bridge, Novartis, Pfizer Inc., Roche, Sanofi-Aventis, and Servier. Lori Stockert, Rajiv Mundayat, and Lisy Wang are employees and stockholders of Pfizer Inc. Christopher T. Ritchlin has acted as a consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc., and UCB and has received grants and/or research support from AbbVie, Janssen, Pfizer Inc., and UCB.

: Both trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Council for Harmonisation and were approved by the relevant Institutional Review Board and/or Independent Ethics Committee of the investigational centers. All patients provided written, informed consent, which is applicable to all medical research conducted using data from these studies, including this post hoc analysis. As all patients provided informed consent, all of the data included in this analysis were covered by the original ethical review/approval process. Consequently, no additional ethical review/approval was required for this post hoc analysis.